USP7、USP14、USP19、USP9x ノックダウン HeLa 細胞

 この製品に関するご意見・ご照会・お問合せはこちら

RNAi is the major approach for studying a targeted gene function with high specificity and selectivity as a reliable alternative to laborious knockout strategies.

LifeSensors is offering SilenciX®, gene-specific knock-down cell lines ‘silencing’ DUBs and/or other important proteins of interest using a unique siRNA delivery system developed by tebu-bio Laboratories*. Based on EBV-replication, SilenciX ensures chromosome-like replication without integration in the genome. Reinforced by an optimal hygromycin selection, this loss-of-function model comes with exceptional features determined by three major factors:

·        Targeting - specific and efficient

·        Stability - homogenous and constant knockdown

·        No off-target effects - genome and transcriptome integrity

Main benefits:

• Efficiency
  - Validation performed by qPCR
  - KD level guarantee: >70%
• Specificity
• High Stability and long term culture: 3-12 months
• No off-target effects
• Non-viral genome integrity
• Safe
• Ready to Use (RTU)

SilenciX® employs a pEBV-derived plasmid delivery system designed to deliver optimal and constant siRNA levels without off-target effects (Biard, 2007). The Epstein-Barr (EBV)-based vector is anchored to chromosomes and replicates as a replicon without any integration in the genome. Reinforced by optimal hygromycin selection, the number of vectors is perfectly maintained. This avoids saturation of the RNAi machinery resulting in specific and homogeneous knockdown of the desired target.

Comparison to traditional RNAi approaches:

Applications of specific knock-down cellular model using SilenciX® technology

• A ready-to-use and stable cellular model of loss-of-function.
• Reliable, functional RNAi assay to rapidly screen and analyze new therapeutics.
• Powerful technology for target validation.
• Cell-based assay development for HTS. Mimic disease phenotypes with target depletion.
• Secondary screening: confirmed hits can be tested in a functional assays offered by SilenciX® catalog and custom cell lines.

PRODUCT INFORMATION
For each cell line, you receive:

• One vial of target specific SilenciX® cells

• One vial of control SilenciX® cells (transfected with a non-relevant shRNA sequence)

• Specification sheets with qPCR quality controls and details of shRNA sequence

•   Complete user manual

References

Despras E, Pfeiffer P, Salles B, Calsou P, Kuhfittig-Kulle S, Angulo JF, Biard DS. Long-term XPC silencing reduces DNA double-strand break repair. Cancer Res. 2007 Mar 15;67(6):2526-34.

*SilenciX® is a registered trademark of tebu-bio; technology licensed from the CEA.

 この製品に関するご意見・ご照会・お問合せはこちら

この製品に関するご意見・ご照会・お問合せはこちら 

New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules, peptides and antibodies being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can.

この製品に関するご意見・ご照会・お問合せはこちら

TLR2かつ/またはTLR7に作用するアゴニスト

 この製品に関するご意見・ご照会・お問合せはこちら

Toll-like receptors (TLRs) are the best studied pattern recognition receptors (PRRs) and their importance in stimulating innate and adaptive immunity is now well established.
TLRs are sensors of microbial components as well as host-derived endogenous molecules released by injured tissues. TLRs play a critical role in defense against invading pathogens but are also involved in other serious pathological processes, such as tumorigenesis [1]. In view of this, TLR agonists have great potential as immunotherapeutics or vaccine adjuvants for the treatment of infectious diseases, cancer and autoimmune diseases.

One of the most successful empiric vaccines ever developed, the live attenuated yellow fever vaccine YF-17D, activates immune cells via multiple TLRs [2]. In the same line, microbial products, such as Coley’s toxin (a mixture of killed Streptococcus pyogenes and Serratia marcescens bacteria) and Bacille Calmette-Guérin (BCG, an attenuated strain of Mycobacterium bovis), which have been used as anticancer agents with some success, induce the host immune system through the activation of several TLRs. Studies have demonstrated that YF-17D and BCG efficacy requires a Th1 cytokine response which promotes antigen-specific cytotoxic T cells [2, 3].

Today, very few TLR agonists are approved for clinical use as stand-alone agents or adjuvants [4]. One of the major challenges of cancer immunotherapy is the reversal of tumor-driven immune suppression. Tumor cells release soluble factors leading to tumor infiltration by immune cells and their convertion into potent immunosuppressive cells. Among the immune suppressor cells, myeloid-derived suppressor cells (MDSCs) are the focus of extensive studies. MDSCs release additional soluble factors that stimulate tumor growth, induce regulatory T cells and suppress CD8+ T cells, thus impairing tumor surveillance and antitumor responses [5]. TLR3 or TLR9 agonists, which elicit strong IFN-α responses, have been shown to induce MDSC maturation and loss of suppressive functions, in contrast to TLR4 agonists which support MDSC suppressive functions [6].

Schematic representation of innate immune signaling pathways activated by PamadiFectin™ (CL553), a multi-PRR agonist that activates TLR2, TLR7 and nucleic acid sensors when complexed with dsDNA, for example.

Given that TLRs are expressed in different cellular compar tments, by different cell types and that they trigger different signaling pathways, combining TLR agonists can act in synergy to promote Th1-type immunity. Encouraging clinical results have been reported with the combination of BCG and the TLR7 agonist Imiquimod in melanoma patients [7]. Furthermore, vaccination studies have demonstrated that the combination of Imiquimod and MPL, a TLR4 ligand, elicits synergistic increases in antigen-specific neutralizing antibodies compared to a single TLR ligand [8].

The combination of TLR agonists with agonists for other PRRs, such as the sensors of nucleic acids RIG-I/MDA-5, IFI16 and cGAS, may fur ther enhance the immune response against cancer and infectious diseases.
With this perspective, InvivoGen has developed multi-PRR agonists that activate TLR2 and/or TLR7 and can complex nucleic acids, such as double-stranded DNA, leading to additional recognition by cytosolic DNA sensors (CDSs). These molecules have been shown to induce a strong immune response in a murine melanoma cancer model and in vaccination studies.

By mimicking the potent natural immuno-stimuli that are viruses and bacteria, multi-PRR ligands represent an interesting new class of agents in cancer immunotherapy or vaccination. However, further studies are needed to develop the best PRR agonist combinations for a given application.

1. Rakoff-Nahoum S. & Medzhitov R., 2007. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 317(5834):124-7.
2. Querec T. et al., 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 tostimulate polyvalent immunity. J Exp Med. 203(2):413-24.
3. Saint F. et al., 2001. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol. 166(6):2142-7.
4. Galluzzi L. et al., 2012. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 1(5): 699–716.
5. Gabrilovich DI. et al., 2012. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 12(4):253-68.
6. Lindau D. et al., 2013. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 138(2):105-15.
7. Kidner TB. et al., 2012. Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother. 35(9):716-20.
8. Kasturi SP. et al., 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 470(7335):543-7.

 Multi-PRR Ligands Products

この製品に関するご意見・ご照会・お問合せはこちら

SUMO化酵素、脱SUMO化酵素、SUMO誘導体

 この製品に関するご意見・ご照会・お問合せはこちら

Deconjugating Enzymes

Deconjugating Enzyme Substrates

Conjugating Enzymes

SUMO

 この製品に関するご意見・ご照会・お問合せはこちら

1μｌのサンプルについて一度に92種類のがんバイオマーカーをアッセイ可能！

 この製品に関するご意見・ご照会・お問合せはこちら

-The only highly multiplexed assay with　no trade-off on data quality
-Quantifies 92 protein biomarkers in　96 samples simultaneously
-Exceptional specificity based on the　Proximity Extension Assay
-Consumes only 1 μL – ideal for　biomarker studies in precious　bio-banked samples such as -serum,　plasma, tissue etc.
-High throughput quantification　– 9,216 datapoints generated per run
-New biomarker panels are developed　and released continuously by Olink　Bioscience

Proseek Multiplex is based on Proximity Extension Assay (PEA) Technology

Biomarkers

 この製品に関するご意見・ご照会・お問合せはこちら

 この製品に関するご意見・ご照会・お問合せはこちら

New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules, peptides and antibodies being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can.

この製品に関するご意見・ご照会・お問合せはこちら

InvivoGen社は、自然免疫分野だけでなく、哺乳類細胞発現分野でも注目製品を数多く販売しています。

InvivoGen社の2012-2013版カタログでは、「自然免疫」と「哺乳類細胞発現」に分冊し発行されることになりました。その第1弾として2012年12月に発行しました自然免疫総合カタログ（日本語版）に続き、第2弾として哺乳類細胞発現総合カタログ（日本語版）を発行しました。

哺乳類細胞発現総合カタログ（日本語版）では、新規分泌型ルシフェラーゼLucia™遺伝子を利用した各種製品を充実すると共に抗体作製用ベクターpFUSE-CHIg/pFUSE-CLIgを充実し、掲載しています。また、従来からご好評いただいていますマイコプラズマ検出・除去試薬や選択用抗生物質など細胞培養用製品も掲載しています（Chapter紹介はこちら(PDF 560KB）)。

カタログがお手元にお届けできていない場合は、弊社営業所、販売取扱店へご連絡ください。

Web siteからのご請求はこちら

InvivoGen社は、自然免疫分野だけでなく、哺乳類細胞発現分野でも注目製品を数多く販売しています。
この度、哺乳類細胞発現総合カタログ（日本語版）を発行しました。これに伴い本カタログ掲載製品を特別価格で提供します。ぜひ、この機会をご利用ください。

StemBeads FGF2は、FDAで承認されている生分解性ポリマーであるPLGA [Poly(lactic-co-glycolic Acid)] にヒトFGF2を結合させたビーズで、培地中で長期にわたり一定濃度のFGF2を徐放します。お使いの培地にStemBeads FGF2を加えることで、従来は毎日必要であった培地交換が2日～3日に1回で済み休日の操作が不要で、培地使用量も節約できます。

特長

*1細胞種、細胞密度によって培地交換の回数の調整が必要となります。
*2現時点で特定の培地に対する不具合は確認されていません。

実施例

StemBeadsで育てたiPS細胞やES細胞のコロニーは典型的な形態を示すことが実証されています。
データご提供：京都大学物質−細胞統合システム拠点 (iCeMS)　長谷川 光一講師、吉田 則子研究員

■ヒト iPS細胞株 253G1*

■ヒト ES細胞株 KhES-1

■ヒト ES細胞株 H9

性能評価1

■FGF量の変化 

従来法によりFGF2を添加した場合、安定性の問題により、FGF2は激減します。StemBeadsを使用すると、3日間一定量でFGF2が徐放されます。

性能評価2

■従来法との未分化マーカーの発現量、核型解析、コロニー形態の比較

MEFフィーダー細胞上で1ヶ月間培養したヒトES細胞のFACS解析では、本製品を添加した培地を3日に一度の培地交換により培養した細胞と従来法により培養した細胞で類似したプロファイルを示します。しかし、qRT-PCRの結果では、NANOGの発現量が著しく上昇し、分化マーカーのSOX17やBrachyuryは著しく減少しました。hESCの正常核型を増殖前に評価して、従来法または本製品使用による増殖後1ヶ月の細胞についても評価しました。その結果、いずれも、異常は確認されませんでした。免疫細胞染色では、本製品の使用と従来法を比較した結果、コロニーの形態や多能性マーカーであるOCT4、NANOGの発現量が類似していました。

性能評価3

■ 従来法とのマウス神経幹細胞における未分化状態維持の比較 

FGF2 Beadsは、マウスの神経幹細胞について未分化状態の維持に優れることが示されています。本製品を添加した培地を用い1週間培養したマウスの神経幹細胞は、従来法やFGF2を含まない場合と比較して前駆細胞（Nestin+）の数が上昇し、神経に分化した細胞（TUJ1+）の数が減少することが示されています（Scale bars=50microns）。 ここには掲載していませんが、ヒトの神経幹細胞でも同様の結果が得られています。

▲戻る

使用方法

1. チューブの底にStemBeadsが沈んでいるため、懸濁液を再混合します。
2. 培地1mlに対し、7.5ulのStemBeadsを混合します。
   細胞種によりますが、細胞密度は低-中程度になるようにしますと、3日間培地交換なしで培養可能となります。
   注）継代翌日に培地交換が必要なケースが多く報告されています。

▲戻る

FAQ

▲戻る

 価格表

ナカライテスク社　プロテインアッセイCBB Clean Up Kit

本製品の使用により、CBB法において、高濃度の界面活性剤や塩類、変性剤を含む溶液のタンパク質定量が可能です。操作は簡単で、タンパク質沈殿法により、これらの妨害物質を除去でき、測定用サンプルの調製が可能です。

使用例

■SDS-PAGE用試料緩衝液に溶解しているタンパク質の定量
妨害物質である還元剤、界面活性剤を共に含む試料緩衝液中のタンパク質(BSA)を測定した結果を示します。A社除去キット使用時には、定量性が得られませんでしたが、本製品では定量性が得られており、除去効果が確認できました。

実施例

以下に妨害物質の例を示します。水色の列は、直接サンプルをCBB法で測定しても影響を与えない妨害物質の最大濃度を示し、紫色の列は本製品を使用した場合の最大濃度を示しています。界面活性剤、変性剤、塩類では妨害物質の影響が大幅に減少しています。
*キレート剤含有または酸性溶液（pH約5以下）の場合、中和もしくは表記載濃度まで希釈してからご使用ください。
   使用前に製品添付文書をご参照ください。

▲戻る

参考情報

本製品を加え遠心操作を行う事で、タンパク質を沈殿させ、妨害物質を除去します。沈殿後のタンパク質にプロテインアッセイCBB溶液を直接添加する事で、定量が可能です。
尚、本製品により0.2～1.0mg/ml濃度のタンパク質溶液を沈殿できます。
＊詳細は製品添付文書をご参照ください。

▲戻る

価格表

 ※記載の内容は、'13年3月現在の情報に基づいております。

ナカライテスク社　プロテインアッセイCBB溶液(Ready To Use)

本製品は、使用時に希釈の手間不要なready to useタイプのタンパク質定量試薬です。

測定範囲

従来のProtein Assay CBB Solution(5x)と測定範囲は同じです

実施例

■マイクロプレートスタンダードアッセイ法によりBSAを定量 

CBB溶液(Ready To Use)は、他社製品と同様の測定範囲を示します。

■使用量が少量

上図のとおり、マイクロプレートスタンダードアッセイ法では、当社製品は少ない試薬量でアッセイでき、ランニングコストを低減できます。

▲戻る

価格表

 ※記載の内容は、'13年3月現在の情報に基づいております。

平素はInvivoGen社商品のご愛顧を賜り厚くお礼申し上げます。
さて、この度InvivoGen社細胞商品について品質安定のため、輸送条件が凍結状態での輸送に変更されますので、お知らせします。
現在の細胞を休眠状態にしたうえでの室温輸送から、凍結状態、ドライアイス梱包での輸送に変更します。

実施日

2013年3月15日（金）　InvivoGen社出荷分より

変更目的

品質安定のため

変更内容

細胞を休眠状態にしたうえでの室温輸送
  ↓
細胞を凍結状態、ドライアイス梱包での輸送

取扱上の注意

当該商品がお手元に到着次第、直ぐに細胞培養をお願いします。

対象商品

コスモシールCholester は、コレステロール由来の固定相構造を有するためC₁₈ カラムで分離できない化合物に対し分離を改善できる逆相クロマトグラフィー用カラムです。今回はC₁₈ カラムでは分離できないコーヒーの有効成分の分析例をご紹介します。

記事は

こちら→

（440KB）

コスモシールHILIC は、トリアゾールを結合させることにより親水性相互作用に加えて陰イオン交換能を有し
ます。この親水性相互作用と陰イオン交換能によりユニークな保持挙動や分離能を示します。

記事は

こちら→

（179KB）

USP7、USP14、USP19、USP9x ノックダウン HeLa 細胞

 この製品に関するご意見・ご照会・お問合せはこちら

RNAi is the major approach for studying a targeted gene function with high specificity and selectivity as a reliable alternative to laborious knockout strategies.

LifeSensors is offering SilenciX®, gene-specific knock-down cell lines ‘silencing’ DUBs and/or other important proteins of interest using a unique siRNA delivery system developed by tebu-bio Laboratories*. Based on EBV-replication, SilenciX ensures chromosome-like replication without integration in the genome. Reinforced by an optimal hygromycin selection, this loss-of-function model comes with exceptional features determined by three major factors:

·        Targeting - specific and efficient

·        Stability - homogenous and constant knockdown

·        No off-target effects - genome and transcriptome integrity

Main benefits:

• Efficiency
  - Validation performed by qPCR
  - KD level guarantee: >70%
• Specificity
• High Stability and long term culture: 3-12 months
• No off-target effects
• Non-viral genome integrity
• Safe
• Ready to Use (RTU)

SilenciX® employs a pEBV-derived plasmid delivery system designed to deliver optimal and constant siRNA levels without off-target effects (Biard, 2007). The Epstein-Barr (EBV)-based vector is anchored to chromosomes and replicates as a replicon without any integration in the genome. Reinforced by optimal hygromycin selection, the number of vectors is perfectly maintained. This avoids saturation of the RNAi machinery resulting in specific and homogeneous knockdown of the desired target.

Comparison to traditional RNAi approaches:

Applications of specific knock-down cellular model using SilenciX® technology

• A ready-to-use and stable cellular model of loss-of-function.
• Reliable, functional RNAi assay to rapidly screen and analyze new therapeutics.
• Powerful technology for target validation.
• Cell-based assay development for HTS. Mimic disease phenotypes with target depletion.
• Secondary screening: confirmed hits can be tested in a functional assays offered by SilenciX® catalog and custom cell lines.

PRODUCT INFORMATION
For each cell line, you receive:

• One vial of target specific SilenciX® cells

• One vial of control SilenciX® cells (transfected with a non-relevant shRNA sequence)

• Specification sheets with qPCR quality controls and details of shRNA sequence

•   Complete user manual

References

Despras E, Pfeiffer P, Salles B, Calsou P, Kuhfittig-Kulle S, Angulo JF, Biard DS. Long-term XPC silencing reduces DNA double-strand break repair. Cancer Res. 2007 Mar 15;67(6):2526-34.

*SilenciX® is a registered trademark of tebu-bio; technology licensed from the CEA.

 この製品に関するご意見・ご照会・お問合せはこちら

SUMO化酵素、脱SUMO化酵素、SUMO誘導体

 この製品に関するご意見・ご照会・お問合せはこちら

Deconjugating Enzymes

Deconjugating Enzyme Substrates

Conjugating Enzymes

SUMO

 この製品に関するご意見・ご照会・お問合せはこちら

この製品に関するご意見・ご照会・お問合せはこちら 

New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules, peptides and antibodies being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can.

この製品に関するご意見・ご照会・お問合せはこちら

TLR2かつ/またはTLR7に作用するアゴニスト

 この製品に関するご意見・ご照会・お問合せはこちら

Toll-like receptors (TLRs) are the best studied pattern recognition receptors (PRRs) and their importance in stimulating innate and adaptive immunity is now well established.
TLRs are sensors of microbial components as well as host-derived endogenous molecules released by injured tissues. TLRs play a critical role in defense against invading pathogens but are also involved in other serious pathological processes, such as tumorigenesis [1]. In view of this, TLR agonists have great potential as immunotherapeutics or vaccine adjuvants for the treatment of infectious diseases, cancer and autoimmune diseases.

One of the most successful empiric vaccines ever developed, the live attenuated yellow fever vaccine YF-17D, activates immune cells via multiple TLRs [2]. In the same line, microbial products, such as Coley’s toxin (a mixture of killed Streptococcus pyogenes and Serratia marcescens bacteria) and Bacille Calmette-Guérin (BCG, an attenuated strain of Mycobacterium bovis), which have been used as anticancer agents with some success, induce the host immune system through the activation of several TLRs. Studies have demonstrated that YF-17D and BCG efficacy requires a Th1 cytokine response which promotes antigen-specific cytotoxic T cells [2, 3].

Today, very few TLR agonists are approved for clinical use as stand-alone agents or adjuvants [4]. One of the major challenges of cancer immunotherapy is the reversal of tumor-driven immune suppression. Tumor cells release soluble factors leading to tumor infiltration by immune cells and their convertion into potent immunosuppressive cells. Among the immune suppressor cells, myeloid-derived suppressor cells (MDSCs) are the focus of extensive studies. MDSCs release additional soluble factors that stimulate tumor growth, induce regulatory T cells and suppress CD8+ T cells, thus impairing tumor surveillance and antitumor responses [5]. TLR3 or TLR9 agonists, which elicit strong IFN-α responses, have been shown to induce MDSC maturation and loss of suppressive functions, in contrast to TLR4 agonists which support MDSC suppressive functions [6].

Schematic representation of innate immune signaling pathways activated by PamadiFectin™ (CL553), a multi-PRR agonist that activates TLR2, TLR7 and nucleic acid sensors when complexed with dsDNA, for example.

Given that TLRs are expressed in different cellular compar tments, by different cell types and that they trigger different signaling pathways, combining TLR agonists can act in synergy to promote Th1-type immunity. Encouraging clinical results have been reported with the combination of BCG and the TLR7 agonist Imiquimod in melanoma patients [7]. Furthermore, vaccination studies have demonstrated that the combination of Imiquimod and MPL, a TLR4 ligand, elicits synergistic increases in antigen-specific neutralizing antibodies compared to a single TLR ligand [8].

The combination of TLR agonists with agonists for other PRRs, such as the sensors of nucleic acids RIG-I/MDA-5, IFI16 and cGAS, may fur ther enhance the immune response against cancer and infectious diseases.
With this perspective, InvivoGen has developed multi-PRR agonists that activate TLR2 and/or TLR7 and can complex nucleic acids, such as double-stranded DNA, leading to additional recognition by cytosolic DNA sensors (CDSs). These molecules have been shown to induce a strong immune response in a murine melanoma cancer model and in vaccination studies.

By mimicking the potent natural immuno-stimuli that are viruses and bacteria, multi-PRR ligands represent an interesting new class of agents in cancer immunotherapy or vaccination. However, further studies are needed to develop the best PRR agonist combinations for a given application.

1. Rakoff-Nahoum S. & Medzhitov R., 2007. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 317(5834):124-7.
2. Querec T. et al., 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 tostimulate polyvalent immunity. J Exp Med. 203(2):413-24.
3. Saint F. et al., 2001. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol. 166(6):2142-7.
4. Galluzzi L. et al., 2012. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 1(5): 699–716.
5. Gabrilovich DI. et al., 2012. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 12(4):253-68.
6. Lindau D. et al., 2013. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 138(2):105-15.
7. Kidner TB. et al., 2012. Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother. 35(9):716-20.
8. Kasturi SP. et al., 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 470(7335):543-7.

 Multi-PRR Ligands Products

この製品に関するご意見・ご照会・お問合せはこちら